Proptosis
Thyroid eye disease plus diabetes increases risk for sight-threatening complications
Adults with thyroid eye disease and diabetes have a higher prevalence of diplopia, strabismus and sight-threatening disease compared with those without diabetes, according to study findings published in Endocrine Practice.
Teprotumumab effective long term, during retreatment for thyroid eye disease
Teprotumumab is effective in reducing proptosis in people with thyroid eye disease more than 2 years after treatment, and initial nonresponders to teprotumumab may benefit from a second series of infusions, according to a speaker.
Thyroid eye disease managed jointly by ophthalmologists and endocrinologists
Not everyone can agree on what to call thyroid eye disease.
Teprotumumab improves short- and long-term clinical outcomes in thyroid eye disease
Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.
Thyroid eye disease present in 40% of people with Graves’ disease
Two of five people with Graves’ disease worldwide have thyroid eye disease, with higher rates among Asian populations vs. other ethnicities, according to a meta-analysis published in Clinical Endocrinology.
Top-line data demonstrate efficacy, safety of teprotumumab for thyroid eye disease
Most adults with thyroid eye disease who experienced meaningful improvement in proptosis after 21 weeks of teprotumumab treatment maintained proptosis response at week 72 without additional treatment, according to top-line data.
Smokers, women experience proptosis reduction with teprotumumab in thyroid eye disease
High-risk adults with active thyroid eye disease, such as smokers, women and older adults, experienced a reduction in outward bulging of the eye at 24 weeks that was similar to adults at lower risk for the disease, according to findings accepted for presentation at the Endocrine Society Annual Meeting.
Teprotumumab improves proptosis, quality of life for adults with thyroid eye disease
Adults with thyroid eye disease assigned the human monoclonal antibody teprotumumab were significantly more likely to experience a meaningful improvement in proptosis after 21 weeks of treatment compared with those who received placebo, according to findings from a randomized controlled trial published in The New England Journal of Medicine.
Teprotumumab significantly improves proptosis in thyroid eye disease
KOLOA, Hawaii — Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.